Clinical trial
An Umbrella Observational Study to Determine Novel Actionable Biomarkers, Mechanisms, and Mitigation of Rare Chimeric Antigen Receptor T Cell (CAR-T) Toxicities in Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07665307 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Umbrella Observational Study to Determine Novel Actionable Biomarkers, Mechanisms, and Mitigation of Rare Chimeric Antigen Receptor T Cell (CAR-T) Toxicities in Relapsed/Refractory Multiple Myeloma (RRMM)
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- July 10, 2026
- Completion date
- June 18, 2029
- Enrollment
- 30 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.